$CTNM SEC Filings

Filed On	Filing
22 Oct 2026	SCHEDULE 13G
01 Oct 2026	144
14 Sep 2026	8-K: Other Events –Phase 2 MOONLIGHT-1 trial did not meet its primary efficacy endpoint
08 Sep 2026	144
08 Sep 2026	Form 4: Stengone Carmine N., Director Received 2,500 shares by exercise or conversion ($2.53K) · Sold 2,500 shares ($41.1K)
01 Sep 2026	144
14 Aug 2026	SCHEDULE 13G/A
03 Aug 2026	Form 4: Stengone Carmine N., Director Received 2,500 shares by exercise or conversion ($2.53K) · Sold 2,500 shares ($40K)
03 Aug 2026	144
03 Aug 2026	144
30 Jul 2026	10-Q
30 Jul 2026	8-K: Results of Operations and Financial Condition
27 Jul 2026	SCHEDULE 13G
17 Jul 2026	SCHEDULE 13G/A
13 Jul 2026	8-K: Regulation FD Disclosure
10 Jul 2026	Form 4: Lorrain Daniel S., Chief Scientific Officer Received 1,015 shares by exercise or conversion ($1.03K) · Sold 1,015 shares ($16.2K) · Received 25 shares by exercise or conversion ($25.3) · 1 more
08 Jul 2026	Form 4: Stengone Carmine N., Director Received 2,500 shares by exercise or conversion ($2.53K) · Sold 2,500 shares ($40K)
08 Jul 2026	144
02 Jul 2026	Form 4: Lorrain Daniel S., Chief Scientific Officer Received 28,826 shares by exercise or conversion ($29.1K) · Sold 28,826 shares ($462K) · Received 4,183 shares by exercise or conversion ($4.22K) · 1 more
01 Jul 2026	Form 4: Watkins Tim, CMO & Head of Development Received 10,833 shares by exercise or conversion ($48.7K) · Sold 10,833 shares ($174K)

Comments